A Phase 3 interventional study of Brexpiprazole in Bipolar I Disorder and Acute Mania, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 73 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-17.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.
Among the 94 studies in Mania with a site in United States, this one is the 12th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2017, is one of 32 in phase 3, and was the 82nd registered.
167 studies on the registry are indexed under Mania; 13 are open to participants now.
Browse Mania studies →5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Bulgaria and 10 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 17 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, China, Croatia and 8 more countries
Ages 18–65
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 6 more countries
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Mania studies recruiting now, 5 (45%) set no upper age limit and 6 (55%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 33 · Phase 4 27
First in 1991; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 381 is above the median of 89 across 138 interventional studies indexed under Mania.
Median enrollment 83 across the 88 interventional studies, 155 across the 6 observational. Of the 87 that completed or were terminated, 40 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 8 studies filed under Mania — fewer than ten, so there is no comparison to draw.
1 of the studies in Mania with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 94 studies in Mania with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar I disorder. All participants received a starting dose of brexpiprazole.
While the availability of atypical antipsychotics had increased the therapeutic options available, there remains a need for safer and more effective therapies in the treatment of manic and depressive episodes of bipolar I disorder. Brexpiprazole's specific receptor activity profile likely correlates with its established efficacy in schizophrenia and major depressive disorder, and may prove to be an effective target for the treatment of acute mania of bipolar I disorder.
Inclusion Criteria (rollover participants from 331-201-00080 \& 331-201-00081 trials)
Exclusion Criteria (rollover participants from 331-201-00080 \& 331-201-00081 trials)
Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
Drug: Brexpiprazole
Brexpiprazole tablets
Also known as: OPC-34712
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. AEs severity were graded on a 3-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, and 3 = severe; inability to work or perform normal daily activity.
Time frame: From Day 1 (after dosing) through 29 weeks (26 weeks treatment, 3 weeks safety follow-up)
| Milestone | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Started | 188 | 193 |
| Analyzed for safety (safety sample) | 184 | 184 |
| Completed | 105 | 100 |
| Not completed | 83 | 93 |
| Withdrew: Adverse event | 14 | 12 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 13 | 19 |
| Withdrew: Non-compliance with study drug | 5 | 9 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Protocol deviation | 2 | 1 |
| Withdrew: Withdrawal by subject | 36 | 43 |
| Withdrew: Early closure of the site | 0 | 1 |
| Withdrew: Physician decision | 5 | 5 |
| Withdrew: Reason not specified | 6 | 3 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. AEs severity were graded on a 3-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, and 3 = severe; inability to work or perform normal daily activity.
| Participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| TEAE, Any grade | 79 | 86 |
| TEAE, Mild | 60 | 68 |
| TEAE, Moderate | 31 | 29 |
| TEAE, Severe | 8 | 5 |
Collected over From Day 1 (after dosing) through 29 weeks (26 weeks treatment, 3 weeks safety follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior Brexpiprazole | 0/184 (0%) | 11/184 (6%) | 13/184 (7.1%) |
| Prior Placebo | 0/184 (0%) | 8/184 (4.3%) | 26/184 (14.1%) |
| Event | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| ManiaPsychiatric disorders | 5/184 | 1/184 |
| DepressionPsychiatric disorders | 3/184 | 2/184 |
| Acute Myocardial InfarctionCardiac disorders | 0/184 | 1/184 |
| Vertigo PositionalEar and labyrinth disorders | 0/184 | 1/184 |
| Upper Gastrointestinal HaemorrhageGastrointestinal disorders | 1/184 | 0/184 |
| Chest PainGeneral disorders | 0/184 | 1/184 |
| CellulitisInfections and infestations | 1/184 | 0/184 |
| MigraineNervous system disorders | 0/184 | 1/184 |
| Bipolar DisorderPsychiatric disorders | 0/184 | 1/184 |
| Suicidal BehaviourPsychiatric disorders | 1/184 | 0/184 |
| Event | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| AkathisiaNervous system disorders | 8/184 | 17/184 |
| HeadacheNervous system disorders | 5/184 | 10/184 |
Enrolled Sample included all participants who signed an inform consent form (ICF) for the trial.
| Age, Continuous(years) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Mean | 45.6 ± 11.0 | 46.1 ± 11.5 | 45.8 ± 11.2 |
| Sex: Female, Male(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Female | 97 | 92 | 189 |
| Male | 91 | 101 | 192 |
| Race/Ethnicity, Customized(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Race — White | 129 | 146 | 275 |
| Race — Black or African American | 52 | 47 | 99 |
| Race — American Indian or Alaska Native | 3 | 0 | 3 |
| Race — Asian | 2 | 0 | 2 |
| Race — Race-Other | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 21 | 24 | 45 |
| Ethnicity — Not Hispanic or Latino | 165 | 169 | 334 |
| Ethnicity — Ethnicity-Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Oct 2017 to primary completion in Jul 2019, 21 months.
Results were first posted in Aug 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →